AzTrials
AzTrials

Metabolic SyndromeNCT04575389

Relation Between Serum Uric Acid and Metabolic Syndrome in Type 2 DM

An observational study of Metabolic Syndrome, run by Assiut University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This study will be undertaken to evaluate the association of serum uric acid (SUA) level with metabolic risk factors in patients with type 2 diabetes and their relation to eGFR status Read more about this study

Who is it for?
Ages 30 to 90 years
Conditions the study is for
Metabolic Syndrome
What is being tested?
Serum uric acid levels ,HBA1C , fasting plasma glucose ,lipid profile , creatinine level
How many people
100 participants
Where
No sites listed yet
Study dates
1 Oct 2020to Nov 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 90 years
  • All sexes
  • Adult, Older adult

Study population: patient will be collected randomly from outpatient clinics of diabetic center of assiut univeristy

Who may be able to join

  • type 2 diabetic patient

Who cannot join

  • patients with type 1 diabetes
  • gestational diabetes
  • patients with drug affecting uric acid levels
  • secondary diabetes

Trial locations and contacts

No sites are listed yet.

esraa tarek, master contact

01004590619

esraatarek062@gmail.com

salah abdelazeem, professor contact

01064559917

argoons@yahoo.com

About this study

Official title: the Association Between Serum Uric Acid Levels and the Risk of Metabolic Syndrome in Type 2 Diabetes Mellitus

This study will be undertaken to evaluate the association of serum uric acid (SUA) level with metabolic risk factors in patients with type 2 diabetes and their relation to eGFR status

Read the detailed description

Metabolic syndrome (syndrome X, insulin resistance) is a multifactorial disease with multiple risk factors that arises from insulin resistance accompanying abnormal adipose deposition and function . It comprises a combination of risk factors for coronary heart disease, as well as for diabetes type 2 , fatty liver, and several cancers.

Sign and symptoms are ; Hypertension... Hyperglycemia.. Hypertriglyceridemia... Reduced high-density lipoprotein cholesterol (HDL-C).. Abdominal obesity... Chest pain or shortness of breath: Suggesting the rise of cardiovascular and other complications.. The prevalence of the metabolic syndrome is often more in the urban population of some developing countries than in its Western counterparts . The syndrome feeds into the spread of the diseases like type 2 diabetes, coronary diseases, stroke, and other disabilities. The present trend is not sustainable unless a magic cure is found (unlikely) or concerted global/governmental/societal efforts are made to change the lifestyle that is promoting it.

There has been a renewed interest in the association of uric acid with diabetes and its complications. Uric acid is a product of purine metabolism. Increased serum uric acid (SUA) level has been shown to be associated with hypertension(1) cardiovascular disease (CVD)(2) and chronic kidney disease(3) . Elevated SUA level was also associated with metabolic syndrome in both normal subjects as well as in patients with type 2 diabetes. And with type 2 diabetes mellitus(4) Higher SUA level independently predicted the incidence of type 2 diabetes in subjects who had abnormal fasting glucose levels (5) . It has been shown that SUA levels are higher in patients with prediabetic conditions and in patients with type 2 diabetes compared with the level in normal controls (6) . SUA level has been shown to be positively associated with all cause mortality risk, but cardiovascular mortality was associated with SUA level only among those with hyperglycemia (prediabetes and type 2 diabetes)(8) . Hyperuricemia has been found to be associated with risk factors of diabetes such as obesity and insulin resistance(9) . Uric acid has also been reported to be involved in the endothelial dysfunction by impairing nitric oxide production and causing inflammation(10) , These effects of uric acid likely account for its impact on CVD incidence(11) . In acute ischaemic stroke, the survivors with both lower (<4.7 mg/dL) and higher (>6.7 mg/dL) baseline SUA levels had poor outcomes after a 12 month follow up when compared with those who had SUA levels in the range of 4.7-6.7 mg/dL. This is suggestive of the protective nature of uric acid when it is within the optimal range.

SUA level was positively associated with increased incidence of cardiovascular diseases (CVD) in patients with abnormal eGFR (<90 mL/min/1.73 m2) . HbA1c was found to be inversely associated with hyperuricemia in patients with normal eGFR level (≥90 mL/min/1.73 m2). Incidence of metabolic syndrome did not show any relationship with SUA level. However, the incidence of hypertension, a component of metabolic syndrome, was significantly higher among patients with hyperuricemia. Waist circumference and serum triglycerides were higher, whereas serum high-density lipoprotein level was lower in patients with higher SUA level. (12) Serum urea and creatinine were elevated in hyperuricemic patients, suggesting impaired kidney function. Hyperuricemia is known to be associated with the decrease in kidney function (13) and because chronic kidney disease itself elevates SUA level,(14) it is difficult to interpret the causes of the elevated serum urea and creatinine in hyperuricemia. However, eGFR values were only slightly lower in hyperuricemic patients. Correlation analysis showed that both serum urea and creatinine levels were positively associated with SUA level.. This association was found to be significant in patients with normal eGFR levels as well. However, eGFR appears to be negatively associated with SUA level in patients with abnormal eGFR level. Decreased urine output leads to decreased excretion of uric acid, resulting in the elevated SUA level. Therefore, reduction in eGFR may increase SUA levels in these patients.

The importance of uric acid has been increasingly appreciated because of its association with the development of diabetes mellitus and related diseases. SUA level and susceptibility to hyperuricemic conditions depend on the factors such as gender, age and ethnicity. (15) With the increasing incidence of diabetes studying the impact of hyperuricemia in patients with diabetes is necessary.

Being tested
Serum uric acid levels ,HBA1C , fasting plasma glucose ,lipid profile , creatinine level
Medical subject headings
Metabolic Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Serum uric acid levels ,HBA1C , fasting plasma glucose ,lipid profile , creatinine levelDiagnostic test

    diagnostic tests

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. the association of serum uric acid (SUA) level with metabolic risk factors in patients with type 2 diabetes

    the incidence of hypertension, a component of metabolic syndrome, is significantly higher among patients with hyperuricemia. Waist circumference and serum triglycerides are higher, whereas serum high-density lipoprotein level is lower in patients with higher SUA level.

    Measured: baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Oct 2020
  2. Study start1 Oct 2020 (estimated)
  3. Primary completionOct 2021 (estimated)
  4. Study completionNov 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Retrospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04575389
Sponsor's protocol ID
metabolic risk factor
Status last verified
Sep 2020
First submitted
29 Sep 2020
Last updated
5 Oct 2020
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Bellows JG. Editorial: Continuing education in ophthalmology. Ann Ophthalmol. 1976 Jun;8(6):649. No abstract available.

    PubMed 937945
  • Fontelo P, Liu F. Finding translational science publications in MEDLINE/PubMed with translational science filters. Clin Transl Sci. 2011 Dec;4(6):455-9. doi: 10.1111/j.1752-8062.2011.00320.x. Epub 2011 Nov 7.

    PubMed 22212228
  • Pozas E, Pascual M, Nguyen Ba-Charvet KT, Guijarro P, Sotelo C, Chedotal A, Del Rio JA, Soriano E. Age-dependent effects of secreted Semaphorins 3A, 3F, and 3E on developing hippocampal axons: in vitro effects and phenotype of Semaphorin 3A (-/-) mice. Mol Cell Neurosci. 2001 Jul;18(1):26-43. doi: 10.1006/mcne.2001.0999.

    PubMed 11461151
  • Wang XR, Robinson KM, Carter-Harris L. Prevalence of chronic illnesses and characteristics of chronically ill informal caregivers of persons with dementia. Age Ageing. 2014 Jan;43(1):137-41. doi: 10.1093/ageing/aft142. Epub 2013 Sep 26.

    PubMed 24072413
  • Turner AJ, Hick PE. Inhibition of aldehyde reductase by acidic metabolites of the biogenic amines. Biochem Pharmacol. 1975 Sep 15;24(18):1731-3. doi: 10.1016/0006-2952(75)90016-7. No abstract available.

    PubMed 16
  • Kunkler I, Jack W, Prescott R, Williams L, King C. Postoperative breast irradiation: new trials needed in older patients. J Clin Oncol. 2003 May 1;21(9):1893; author reply 1893-4. doi: 10.1200/jco.2003.99.239. No abstract available.

    PubMed 12721273
  • Woods DJ. Conceptualizing depression and its treatment: comparison of psychoanalytic and behavioral approaches. Psychol Rep. 1975 Dec;37(3 PT 2):1271-8. doi: 10.2466/pr0.1975.37.3f.1271. No abstract available.

    PubMed 1823
  • Dupuy B, Mounier J, Blanquet P. [Some comments on the biological properties of calcitonin: an eventual new therapeutic utilization (author's transl)]. Ann Endocrinol (Paris). 1977 Jul-Aug;38(4):323-6. French.

    PubMed 561566
  • Fritsch P, Honigsmann H, Jaschke E, Wolff K. [Photochemotherapy of psoriasis: increasing its effectiveness with an oral aromatic retinoid (clinical results in 134 patients) (author's transl)]. Dtsch Med Wochenschr. 1978 Nov 3;103(44):1731-6. doi: 10.1055/s-0028-1129333. German.

    PubMed 361362
  • Bundgaard H. Polymerization of penicillins: kinetics and mechanism of di- and polymerization of ampicillin in aqueous solution. Acta Pharm Suec. 1976;13(1):9-26. No abstract available.

    PubMed 3942

Questions about this trial

What is this clinical trial studying?

An observational study of Metabolic Syndrome, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 5 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact esraa tarek, master (01004590619, esraatarek062@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

the association of serum uric acid (SUA) level with metabolic risk factors in patients with type 2 diabetes (time frame: baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04575389, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in